---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-26-000047"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-09-08T12:34:27+00:00"
generated_at: "2026-09-08T12:35:13.582398+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mirum names Rob Myers CMO; Joanne Quan exits with severance

## Summary
- Rob Myers, M.D. appointed Chief Medical Officer, effective Sept 21, 2026, succeeding Joanne Quan, M.D.
- Joanne Quan ceased as CMO Sept 2, 2026; employment termination expected Oct 19, 2026.
- Separation agreement: vested stock option exercise period extended to 12 months post-separation; 2026 annual bonus paid at 100% target.
- Benefits contingent on customary conditions; separation qualifies as involuntary under Severance Plan.

## SEC filing metadata
- accession: 0001759425-26-000047
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-09-08T12:34:27+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/0001759425-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-26-000047
- JSON: https://secwatch.observer/filing/0001759425-26-000047.json
- Plain text: https://secwatch.observer/filing/0001759425-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.